In this study, we address one of the major critiques for tumor-infiltrating lymphocyte (TIL) therapy-the time needed for proper expansion of a suitable product. We postulated that T-cell receptor activation in the first phase of expansion combined with an agonistic stimulation of CD137/4-1BB and interleukin-2 would favor preferential expansion of CD8 + TIL. Indeed, this novel 3-signal approach for optimal T-cell activation resulted in faster and more consistent expansion of CD8 +
C linical success using tumor-infiltrating lymphocytes (TIL) in adoptive cell therapy (ACT) has been widely reported in previous phase II studies. [1] [2] [3] [4] Although this success has predominantly been reported in metastatic cutaneous melanoma, given its pioneering status, TIL therapy was later transposed in other malignancies such as colon cancer, HPV-related cervical cancer, and uveal melanoma. [5] [6] [7] The methodology for sufficiently expanding numerous TIL is primarily dependent on an initial stage of in vitro expansion of TIL from tumor fragments (referred to as the "pre-REP" process), followed by a large scale expansion and infusion using the rapid expansion protocol (REP). The strategy for the expansion of TIL in the pre-REP process has been solely based on providing a strong signal for T-cell activation through exogenous addition of high-dose interleukin (IL)-2, without direct activation of the T-cell receptor (TCR). Following culturing in high-dose IL-2, TIL expansion occurs within 3-5 weeks. Although the techniques used for the expansion of TIL in the pre-REP process are very consistent for metastatic cutaneous melanoma, the final yield of TIL and the time required to attain those numbers are highly variable. It is noteworthy that this variability is not only contingent on the level of infiltration of TIL in the tumor fragments. This is clearly demonstrated in uveal melanoma where the ability to successfully culture TIL in the pre-REP phase is low despite the degree of TIL infiltration in the original tumor fragments comparable with the degree of infiltration in cutaneous melanoma. 8 Consequently, we aimed to overcome 3 major challenges of pre-REP TIL manufacturing: patient's accessibility to therapy, time required to expand TIL, and expertise required to culture TIL given its variability without compromising the degree of T-cell differentiation or tumor reactivity. We first hypothesized that the type of activation given by high-dose IL-2, which would be considered a "third signal" for T-cell activation, might not be sufficient to expand TIL in malignancies like uveal melanoma where the level of T-cell infiltration does not correlate with successful pre-REP expansion of TIL. Therefore, we decided to optimize the generation of the pre-REP product by combining the 3 signals required for an optimal T-cell activation: translating in the addition of OKT3 antibody (anti-CD3) for TCR stimulation (signal 1) and the use of an agonistic antibody to CD137/4-1BB (a-4-1BB, Urelumab) (signal 2 for costimulation), while keeping high-dose IL-2 for the third signal. The choice of an agonistic stimulation of 4-1BB over other costimulatory molecules was based on our extensive experience in multiple cancer types and the previous demonstration that addition of this agonistic antibody during the REP phase preserved melanoma TIL from over differentiation and protects against activation-induced cell death. [9] [10] [11] [12] Altogether, this work describes how targeting the 3 signals combined for T-cell activation significantly improved the success of TIL culturing. In addition, we show greatly reduced variability in time and yield of TIL for the pre-REP process while preserving the capacity for tumor recognition. It is our hope that the standardization of growth conditions will improve the eligibility of patients to TIL ACT for challenging cancer types such as uveal melanoma or when tissue size is a limiting factor. Finally, the development of a reliable and standard TIL manufacturing methodology will facilitate expansion of TIL therapy to additional treatment centers and broaden the pool of treatment eligible patients.
MATERIALS AND METHODS

Patient Selection
All melanoma TIL lines were derived from tumor tissue obtained from patients with metastatic melanoma (or primary tumor in some uveal cases) who provided written informed consent for a TIL ACT clinical trial [Institutional review board (IRB)-approved protocol# 2004-0069, NCT00338377] at the University of Texas MD Anderson Cancer Center (MDACC). Male and female patients over the age of 12 with stage IV melanoma, stage III in-transit disease, recurrent regional nodal disease, or uveal melanoma were eligible for enrollment. Refer to clinical trial NCT00338377 on www.clinicaltrials.gov for specific exclusion criteria. For this study, samples from cutaneous (n = 18) and uveal (n = 12) melanoma patients were assessed.
Reagents
A fully human and purified IgG4 monoclonal antibody against human CD137 (Urelumab, 663513; Lot 6A20377) was kindly provided by Bristol Myers Squibb (BMS, New York, NY) through a Materials Transfer Agreement. Human recombinant IL-2 (Proleukin) was generously provided by Prometheus Therapeutics and Diagnostics (San Diego, CA). GMP-grade soluble anti-CD3 antibody (OKT3 clone) was obtained from Miltenyi Biotec (Bergisch Gladbach, Germany).
Isolation and Expansion of TIL From Human Metastatic Melanoma Tumors (Clinic vs. New)
With regard to the clinic TIL line generation, the tumor samples were cut into 1-3 mm 3 fragments and placed in complete TIL culture media (TIL-CM) and 6000 IU/mL IL-2. TIL were cultured in 24-well plates for a period averaging between 3 and 5 weeks. An average of 20 fragments were put in culture in 24-well plates (1 fragment/well). 2,13 For 3-signal expansion, five 1-3 mm 3 fragments were put in culture in a G-Rex 10 flask (Wilson Wolf Manufacturing, New Brighton, MN) in 20 mL of TIL-CM with 30 ng/mL of OKT3, 10 μg/mL of agonist 4-1BB antibody, and 6000 IU/ mL IL-2. 4 to 5 days after initiating the culture, 20 mL of TIL-CM containing 6000 IU/mL IL-2 were added for a total of 40 mL. Half of the media was replaced with new TIL-CM containing 6000 IU/mL IL-2 every 3-4 days until the cells completely covered the bottom of the flask. The cell suspension was filtered with a 40 μm cell strainer (Corning, Tewksbury, MA) before performing flow analysis and cryopreservation for later testing. The 4-1BB condition was carried in the same manner but without addition of OKT3. TIL lines were terminated after 3 weeks of culture in absence of TIL growth. All samples described are from the same tumor tissue tested across expansion methods as indicated by the 4 digit deidentified patient ID in each figure.
Flow Cytometric Analysis of TIL
Expanded TIL were stained in 100 μL of FACS wash buffer (Dulbecco's phosphate-buffered saline 1× with 1% bovine serum albumin) for 30 minutes using fluorochromeconjugated monoclonal antibodies for CD3 (FITC), CD16 (PE), γδTCR (APC), CD56 (PE-Cy7), CD4 (PerCP-Cy5.5), CD8 (PB), BLTA (PE), CD28 (PE-Cy7), TIM3 (APC) (all BD Bioscience, San Jose, CA), PD-1 (PerCP-Cy5.5) (Biolegend, San Diego, CA), and AQUA live/dead dye (Invitrogen, Carlsbad, CA). Stained cells were acquired using the BD FACSCanto II and analyzed using FlowJo software v 10.1 (Tree star, Ashland, OR).
Interferon (IFN) γ Enzyme-linked Immunospot (ELISPOT) Assay
IFNγ ELISPOT assay was performed as described by Harao et al. 10 Briefly, MultiScreen-HA 96-well filter ELI-SPOT plates (Millipore, Billerica, MA) were coated with 5 μg/mL anti-IFNγ mAb (Mabtech, Cincinnati, OH) in pH 9.5 carbonate buffer (Sigma-Aldrich, St.Louis, MO) overnight at 4°C and blocked with 2% bovine serum albumin of phosphate-buffered saline (Sigma). OKT3+a-4-1BB expanded TIL fragments were thawed and rested overnight in TIL-CM with 6000 IU/mL of human IL-2 in 37°C. The following day, cells were washed twice and rested in TIL-CM without IL-2 for 6 hours at 37°C. Before setting the coculture experiment, 1×10 5 cells/well (or indicated numbers of cells/well, for #3111: 5×10 4 , for #3116: 2×10 4 ) of autologous tumor were incubated in the presence of 80 μg/mL of mouse IgG2a kappa isotype control Ab (eBioscience, San Diego, CA) or anti-Human HLA-ABC mAb (clone W6/32, eBioscience) for 3 hours as previously described. 14 In total, 1×10 5 cells/well of rested TIL were cocultured with autologous tumor lines in triplicates for overnight. The next day, 1 μg/mL of biotin-labeled anti-IFN-γ mAb (Mabtech) was added and incubated for 1 hour at 37°C. After treatment with a 1: 5000 dilution of extravidin-alkaline phosphatase (Sigma) for 1.5 hours at room temperature, plates were developed with filtered 5-bromo-4-chloro-3-indolyl-phosphate in conjunction with nitro blue tetrazolium (BCIP/NBT substrate; Sigma). Spots were counted on an ImmunoSpot ELI-SPOT reader (CTL Immunospot Reader, software version 6.0.0.0, Cleveland, OH). TIL only with media condition is a negative control (TIL alone). Cells treated with Phorbol 12-myristate 13-acetate and ionomycin (Sigma) were used as positive controls in this experiment. The culture was considered reactive to the tumor line when the isotype control was twice that of the MHC class I blocked condition.
Statistical Analysis
GraphPah prism version 7 (GraphPad Software, La Jolla, CA) was used for graphing and statistical analysis. Mean ± SD were calculated for each condition and statistical analysis for comparison of culture duration was performed using an unpaired Student t test with the Welch correction. The clinical expansion conditions were used as a control metric for determination of statistical significance unless otherwise stated in the figure.
RESULTS
Retrospective Success of TIL Expansion at the Pre-REP Stage Over 11 Years at MDACC the 11 years of this protocol's existence. As we opted for a "banking" model instead of an "intent to treat only" model, the MDACC TIL lab has accumulated an impressive bank of cryopreserved TIL. Successful TIL culture is defined as the ability to grow at least 40×10 6 cells by 5 weeks. The culturing success rate throughout 11 years averages at 62%, with 68% for the last 5 years (n = 1135, depicted in Fig. 1 ). Pre-REP TIL are obtained by cutting fragments of r3 mm 3 and culturing them in 24-well plates with high doses of IL-2 for a maximum of 5 weeks before cryopreservation (Fig. 1, schematic) . There is no discrimination in tissue accrual based on quality or size.
Simultaneous Engagement of the TCR and CD137/4-1BB Molecule Shortens the Duration and Improves the Success Rate of TIL Expansion in Both Cutaneous and Uveal Melanoma
The labor and expertise required to care for the pre-REP stage including the high variability in the number of TIL obtained and the duration of the culture have warranted research efforts to streamline and standardize this procedure. We and others have recently published for multiple solid cancers, including cutaneous melanoma, that the use of an agonistic antibody directed at CD137/4-1BB (Urelumab) expressed on the surface of CD8 + TIL could improve the growth rate and reduce the time of propagation of pre-REP TIL. 9, 10, 15 Although the introduction of 4-1BB stimulation presents a great advantage, it does not take the expertise and decision-making factor out of the equation throughout the culturing process. On the basis of our past experiences on the use of different devices for TIL expansion and their beneficial effect on metabolism, we designed a new approach to expand pre-REP TIL. This new approach also took into account data showing that some cultures (mainly from uveal melanoma) grow poorly in IL-2 alone but expand well after a TCR activation, as well as our knowledge of the benefit of a CD137/4-1BB costimulation of TIL while stimulating the TCR during the REP. 8, 9, 16 This novel method, which utilizes the 3 signals required for an optimal T-cell activation, incorporates the use of both an agonistic 4-1BB and OKT3 antibodies (anti-CD3) with high-dose IL-2 in a small G-Rex10 device. We optimized this new method by using parallel TIL cultures from consented patients. We compared the yield of TIL obtained and duration of culture between our current clinical expansion in 24-well plates with high-dose IL-2 and the 2 other test conditions which were the use of the agonistic 4-1BB antibody alone with IL-2 or the use of the 3 signals (antibodies to 4-1BB and CD3 with IL-2). As demonstrated in Figure 2A , utilizing all 3 signals for T-cell activation in the tumor fragments yields high numbers of TIL in a shorter period of time with an average culture duration of 14.7 ± 2.6 days (white squares, P < 0.0001 as compared with control clinical expansion). By comparison, the culture period for the other 2 growth conditions, while significantly different, was more comparable with an average culture duration of 30.9 ± 6.1 days for the TIL grown for clinical growth (black diamonds) and 24.3 ± 7.8 days for a-4-1BB alone (red squares, P = 0.0119). The TIL grown via the clinical lines in Figure 2A constitutes a good representation of our yearly overall success for melanoma in general (between 60% and 70%). It should be noted that the TIL grown from the clinical cultures arise from an average of 20 fragments in 24-well plates; in contrast to the new method and the agonistic 4-1BB alone where only 5 fragments are used in the G-Rex flask. All data points for all conditions for a given patient came from TIL generated with the same source tissue to ensure maximal standardization. Overall, the addition of agonistic 4-1BB and OKT3 antibodies greatly improved the yield of TIL and halved the culture time required to produce an adequate number of TIL.
Uveal melanoma is notoriously difficult to expand enough TIL to allow for treatment. Contrary to the notion that uveal melanoma tumors are devoid of an immune infiltrate, our colleagues have recently demonstrated that uveal melanoma tumors contain a comparable immune infiltrate compared with cutaneous melanoma. However, the overall numbers obtained after culturing in high-dose IL-2 remain modest in comparison with cutaneous melanoma. 8 As demonstrated in Figure 2B , an agonistic stimulation of 4-1BB combined with the use of OKT3 in the tumor fragments allowed uveal melanoma-derived TIL to proliferate to very high numbers in half the normal culture time (average culture duration of 15.8 ± 2.3 d). The latter is greatly contrasting to the samples grown with only IL-2 in the clinical lab, from which only 3 cultures were considered successful according to our clinical standard from 20 fragments (average culture duration of 29.7 ± 6.5 d, P < 0.0001, Fig. 2B ).
Utilizing the 3 Signals Preferentially Expands the Lymphocyte Population, Mainly the CD8 + TIL
As previously mentioned, addition of the agonistic 4-1BB antibody accelerates the culture process and success rate. However, it also has the potential to stimulate the growth of other tumor-infiltrating immune cells such as natural killer (NK) cells and γδ T cells due to their surface expression of CD137/4-1BB. 17 In a quest to verify if this observation was transposable to our work, we assessed the general phenotype of the pre-REP product obtained from the 3 different methods of expansion. As depicted in Figure 2C (left graph), TIL lines such as TIL#3102 and #3103 expanded more CD3 − (gray bar), most likely NK cells, when the propagation was executed with anti-4-1BB alone. In contrast, the combination with OKT3 gave rise to a more uniform CD3 + T-cell product (Fig. 2C, left graph) . Although specific examples of CD3 − cell growth occurred with agonistic 4-1BB expanded cultures, CD3 + T-cell expansion was generally similar across the growth conditions (average 91.5% clinic, 90% a-4-1BB, and 94% OKT3+a-4-1BB, Fig. 2C, right graph) . We observed a similar result with regard to γδ T cells when we characterized the CD3 + T-cell populations. As shown in Figure 2D , while γδ T-cell expansion was favored in the presence of agonistic 
4-1BB alone in some cases, CD8
+ TIL were predominantly expanded from the tumor fragments when the 3-signal method was used for pre-REP TIL expansion (mean, 84.9% ± 9.6% vs. 74.7% ± 28.1%, P = 0.2). Although this new expansion method resulted in a high degree of TIL proliferation in a short timeframe, we observed a high expression of CD28 and B-and-T lymphocyte attenuator and a low expression of PD-1 and TIM3 indicating that the TIL were not overly differentiated ( Supplementary Fig. 1 , Supplemental Digital Content, http://links.lww.com/JIT/A504). Our group has previously reported that expression of B-and-T lymphocyte attenuator (and CD28) on CD8 + TIL is a signature of less-differentiated TIL, which correlates with clinical response to TIL therapy. 2, 18 TCR-dependent Proliferation Expands Tumor-specific TIL in Both Cutaneous and Uveal Melanoma T cells proliferate and accumulate at sites that are rich for the antigen they recognize. Success of TIL therapy relies on a diverse repertoire of tumor-antigen-specific T cells infiltrating the tumor, and their capacity to recognize various antigens presented by the tumor. As this new method considerably changes the way to expand TIL at the pre-REP level, we wanted to verify if the short-term expanded TIL could recognize their autologous tumor line. As demonstrated in Figure 3A , 4 of 5 cutaneous TIL lines tested displayed tumor recognition based on secretion of IFNγ detected by ELISPOT. This recognition was MHC class I dependent with the exception of the TIL line #3109 which contained 30% NK cells, providing a potential explanation for the presence of IFNγ independently of the availability of the MHC-I complex (Figs. 2C, 3A) . Globally, tumor recognition is not lost upon expansion using this new method.
Tumor cell lines derived from a uveal tumor are always very challenging to generate. We were able to successfully derive 1 autologous tumor cell line for TIL #3121 with confirmed MHC class I expression and mainly devoid of CD90 + fibroblasts ( Supplementary Fig. 2 , Supplemental Digital Content, http://links.lww.com/JIT/A504) which was (Fig. 3B) . Unfortunately, the clinical sample did not proliferate in high-dose IL-2 and tumor reactivity could not be tested. We also tested the uveal pre-REP TIL line #3116 against its autologous tumor that had unfortunately entered in vitro senescence and we could not see any tumor recognition for this line. Therefore, providing the 3 signals attributed to T-cell activation lead to expansion of TIL capable of recognizing their tumor counterpart in cutaneous and uveal melanoma.
DISCUSSION
TIL ACT for metastatic melanoma has demonstrated high clinical response rates in multiple phase II studies; however, the ability to reach widespread application will rely on the standardization and efficiency of TIL expansion methodology. The duration of TIL manufacturing remains a hurdle to overcome in order to translate this therapy to more aggressive tumor types. With this work, we have addressed the variability derived from culturing TIL with IL-2 alone by the combination of IL-2, agonistic CD137/4-1BB (Urelumab) and OKT3 antibodies. This combination resulted in a standard production of TIL in terms of success rate and production time. The production time was consistent at~2 weeks and required minimal manipulation which greatly diminished the need for any decision-making by the operator, thus, abrogated the requirement for expertise in TIL culturing.
One major aspect that needs to be highlighted about this method is that the numbers of TIL obtained from only 5 fragments of r3 mm 3 were equivalent or higher to those obtained from 20 fragments with the standard IL-2 method. Typically, TIL centers set-up variable numbers of fragments in their initial pre-REP culture using IL-2 alone but it usually stands between 20 and 48 tumor fragments. 2, 15 The fact that we easily achieve 100×10 6 TIL from 5 tumor fragments within 2 weeks opens the possibly of expanding TIL successfully from samples as small as a core needle biopsy. One could also contemplate using more TIL fragments with the 3-signal expansion method and treat a patient using only the pre-REP TIL product, thereby omitting the 2 week REP process.
Remarkably, this new approach resulted in 12 of 12 successful expansion of pre-REP TIL derived from uveal melanoma. In comparison, only 3 cultures from a uveal tumor were successfully expanded in the clinical lab using IL-2 alone. From our past experience, the success of generating TIL from uveal melanoma has been poor compared with cutaneous melanoma. 8 Therefore, this method not only reduced variability but, more importantly, allowed reliable growth of TIL from tumor tissue where IL-2 alone was not successful. This enables the possibility of expanding the use of TIL therapy to more patients, including uveal melanoma, where TIL therapy has already shown preliminary success. 7 This advance may help position TIL therapy as a sensible alternative in malignancies facing limited success with the in vivo T-cell activation through the use of checkpoint inhibitors such as uveal melanoma, pancreas adenocarcinoma and triple-negative breast cancer. [19] [20] [21] The general profile of TIL was shifted in favor of CD3 + CD8 + cells when costimulated with agonistic CD137/ 4-1BB and OKT3 antibodies. NK cells can also be stimulated through targeting the 4-1BB axis, which is what was observed when 4-1BB was targeted alone. However, in combination with OKT3, the cultures retained a high percentage of CD3 + T cells through TCR stimulation, avoiding any unwanted stimulatory effects of 4-1BB alone on other cell types.
The very last aspect that we wanted to assess is tumor recognition. Even though our clinical TIL study never correlated tumor recognition with clinical response, it was still critical for us to demonstrate that such a short and strong expansion would not impair the capacity of the pre-REP TIL to recognize an autologous tumor. We were able to demonstrate the latter in both cutaneous and uveal melanoma.
Altogether, utilizing T-cell activation signals 1, 2 and 3 greatly improved the culture success rate and absolute expansion numbers and, more importantly, consistently shortened the duration of pre-REP TIL culture for both cutaneous and uveal melanoma. This study broadens the horizon for TIL therapy in cancers where the amount of tissue available for culture is minimal, as well as for rapidly progressing cancer types where the window of treatment is limited and where the time for TIL production becomes of paramount importance.
